万泰生物股价下跌2.65% HPV疫苗销售不及预期拖累业绩

Core Viewpoint - WanTai Bio's stock price has declined due to increased market competition and disappointing sales of its HPV vaccines, leading to significant revenue and profit losses in the first half of 2025 [1] Financial Performance - As of August 27, 2025, WanTai Bio's stock price was 58.89 yuan, down 1.60 yuan or 2.65% from the previous trading day [1] - The company reported a revenue of 844 million yuan for the first half of 2025, a year-on-year decrease of 38.25% [1] - WanTai Bio experienced a net loss attributable to shareholders of 144 million yuan, a decline of 155.3% year-on-year [1] Business Overview - WanTai Bio's main business includes the production of biological products, with key products being HPV vaccines and in vitro diagnostic reagents [1] - The company's self-developed domestic bivalent HPV vaccine "Xinkening" previously broke the import vaccine monopoly, but has faced intensified competition recently [1] - The newly approved nine-valent HPV vaccine "Xinkening 9" is facing challenges in market expansion due to price competition from imported brands [1] Market Activity - On August 27, 2025, the net outflow of main funds was 91.64 million yuan, with a cumulative net outflow of 3.88 million yuan over the past five days [1]